Dubai 1st May 2017
BIOSERA (France) signed an exclusive distribution agreement with Alliance Global to bring their highest quality serum portfolio to AGBL’s market.
“BIOWEST’s diverse serum and cell culture media products will complement the AGBL Cell Biology range of products and support our customers in academia, governmental and industrials markets.” said Fatima Kakal, Product Manager Cell and Molecular Biology Division at Alliance Global Group.
“BIOSERA is enthusiastic regarding the collaboration between AGBL and BIOSERA for the MEAA region. With AGBL’s extended range and strong distribution network, BIOSERA couldn’t have found a better partner to distribute its product range on the MEAA region.” Said Samuel Boutin, Sales director at BIOSERA
BioSera – The European leader in the collection of animal sera
Founded in 2002, BioSera is a European leader in animal sera and cell culture reagents. It became part of the SeraScandia group in 2012 to join the first serum company vertically integrated from raw material to finished product. Their products are employed in the production of biopharmaceuticals and vaccines and in the academic, governmental and industrial research sectors in fields spanning the areas of cell biology, genomics, proteomics, virology, immunology, innovative drug research and toxicology.
The production plant of the group is located in France and is certified ISO 9001 : 2015 and ISO 13485 : 2012 (Biowest SAS France facility).
For more information please visit: www.biosera.com
About Alliance Global Group (AGBL)
The AGBL Group of companies is the largest biomedical gateway to the emerging markets of the Middle East, Africa and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the emerging healthcare markets within the MEAA region. The group’s stated mission is to improve the lives of the region’s inhabitants through novel biomedical technologies and products. For more information, please visit: www.agbl.net
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future uses, quality or performance of, or benefits of using, products or technologies, the expected benefits of the agreement between AGBL and Cell Signaling Technologies and other future events.
AGBL undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.